Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review and meta-analysis.

Author: CariniMarco, CoronaGiovanni, FicarraVincenzo, GacciMauro, MaggiMario, NovaraGiacomo, SebastianelliArcangelo, SerniSergio, ShariatShahrokh F, ZattoniFiliberto

Paper Details 
Original Abstract of the Article :
INTRODUCTION: Several drugs, currently used to treat lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH), can be associated with bothersome sexual side effects, including ejaculatory dysfunction (EjD). AIM: To provide a systematic review and meta-analysis of the available ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://pubmed.ncbi.nlm.nih.gov/24708055

データ提供:米国国立医学図書館(NLM)

Navigating the Desert of Benign Prostatic Hyperplasia (BPH)

Benign prostatic hyperplasia (BPH) is a common condition that affects men, often leading to lower urinary tract symptoms (LUTS). This study explores the impact of medical treatments for BPH on ejaculatory function, a sensitive issue for many men.

The authors conducted a systematic review and meta-analysis of randomized clinical trials investigating the effects of alpha-blockers, 5-alpha reductase inhibitors (5ARIs), and combination therapy on ejaculatory dysfunction (EjD). The results revealed that both alpha-blockers and 5ARIs were associated with a significantly higher risk of EjD compared to placebo. Furthermore, combination therapy led to a greater risk of EjD compared to either treatment alone.

A Desert Oasis of Knowledge

This meta-analysis provides a valuable roadmap for understanding the potential side effects of BPH medications on ejaculatory function. The findings suggest that specific alpha-blockers, such as Tamsulosin and Silodosin, may carry a higher risk of EjD than others. It is also noteworthy that the effectiveness of a given medication was correlated with the likelihood of EjD, highlighting the need for careful consideration of potential side effects alongside treatment efficacy.

A Camel's Compass for BPH Treatment

This research emphasizes the importance of open communication between patients and healthcare professionals regarding the potential side effects of BPH medications. While medications can provide relief from LUTS, it is crucial to weigh the benefits against the potential impact on sexual function.

Dr. Camel's Conclusion

This research, a journey through the desert of BPH treatment, emphasizes the need for a nuanced understanding of the potential side effects of medications. By weighing the benefits and risks, patients and healthcare providers can make informed decisions that prioritize both physical health and quality of life.

Date :
  1. Date Completed 2014-09-29
  2. Date Revised 2022-03-10
Further Info :

Pubmed ID

24708055

DOI: Digital Object Identifier

S1743-6095(15)30799-2

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.